Working… Menu

Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00434213
Recruitment Status : Completed
First Posted : February 13, 2007
Results First Posted : March 6, 2009
Last Update Posted : April 26, 2017
Information provided by (Responsible Party):
Noven Therapeutics

Brief Summary:
This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks.

Condition or disease Intervention/treatment Phase
Attention Deficit Hyperactivity Disorder Drug: Daytrana Phase 4

Detailed Description:
This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks. Subjects will be titrated to an optimum dose of study treatment and assessed for safety and efficacy. Dermal response will be evaluated at each visit by the investigator. Subjects with high dermal response scores or scores that persist at the same application site and have no improvement after up to 4 evaluations (not to exceed a two week period) will be discontinued from the study and referred to a study specific dermatologist for specialized skin sensitivity skin patch testing.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 309 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IV, Multi-center, Open-label Study of DAYTRANA (Methylphenidate Transdermal System [MTS]) to Characterize the Dermal Reactions in Pediatric Patients Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD).
Study Start Date : January 2007
Actual Primary Completion Date : August 2007
Actual Study Completion Date : July 2008

Arm Intervention/treatment
Experimental: Methylphenidate Transdermal System
To characterize the dermal reactions seen with the use of DAYTRANA
Drug: Daytrana
Methylphenidate Transdermal System (MTS)
Other Name: MTS

Primary Outcome Measures :
  1. Dermal Reactions [ Time Frame: 7 weeks ]
    Dermal reactions were graded on a scale ranging from 0 (no irritation) to 7 (strong reaction) for observed findings of erythema, edema, papules, and vesicles.

Secondary Outcome Measures :
  1. Contact Sensitization to Methylphenidate [ Time Frame: 7 weeks ]
    Contact sensitization to methylphenidate through skin patch testing.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must sign informed consent.
  • Male or female 6-12 years old.
  • Negative pregnancy test.
  • Meet Diagnostic and Statistical Manual of Mental Disorders, 4th edition - Text Revision (DSM-IV-TR) criteria for a primary diagnosis of ADHD.
  • No co-morbid illness that could affect safety, tolerability or interfere with participation.
  • Blood pressure (BP) within the 95th percentile for age, gender, and height.
  • Willing and able to comply with all the requirements defined in protocol.

Exclusion Criteria:

  • Current controlled (requiring a restricted medication) or uncontrolled co-morbid psychiatric diagnosis (except Oppositional Defiant Disorder [ODD]).
  • At risk for suicidal or violent behavior towards self or others.
  • History of a suicide attempt.
  • History of a structural cardiac abnormality or other serious cardiac problems.
  • Non-responder to psychostimulant treatment.
  • Is overweight.
  • Seizures during the last 2 years (exclusive of infantile febrile seizures), a tic disorder, a current diagnosis and/or family history of Tourette's Disorder.
  • Has Conduct Disorder.
  • Known history of alcohol or other substance abuse within the last 6 months.
  • Any abnormal thyroid function.
  • A concurrent chronic or acute illness, disability, or other condition that might confound results of safety assessments.
  • Has had treatment with any known liver altering agents within 30 days prior to Screening.
  • Taking any excluded medication.
  • Previous use of DAYTRANA.
  • Taking other medications that have Central Nervous System (CNS) effects.
  • Female subject is pregnant or lactating.
  • Has any skin disease, or history of any chronic skin disease, skin cancer, skin manifestations of allergic disease, or other dermatologic conditions.
  • Has sensitive-skin syndrome or has sensitivities to the ingredients in soaps, lotions, cosmetics or adhesives.
  • Has clinical signs and symptoms of skin irritation or hyper/hypopigmentation at the potential application sites.
  • A documented allergy, hypersensitivity or intolerance of methylphenidate (MPH) or any components found in DAYTRANA.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00434213

  Show 29 Study Locations
Sponsors and Collaborators
Noven Therapeutics
Layout table for investigator information
Principal Investigator: Timothy Wilens, MD Harvard Medical School

Publications of Results:
Layout table for additonal information
Responsible Party: Noven Therapeutics Identifier: NCT00434213     History of Changes
Other Study ID Numbers: SPD485-411
First Posted: February 13, 2007    Key Record Dates
Results First Posted: March 6, 2009
Last Update Posted: April 26, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Central Nervous System Stimulants
Physiological Effects of Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents